Evidence map›Paper›PMID 36133901›Full record

ArticleCanadian liver journal2022

Early diagnosis and successful long-term management of a rare, severe lysosomal acid lipase deficiency/Wolman disease patient: Infancy to age five.

Antoine Cossette, Julie Castilloux, Chantal Bouffard, Julie Laflamme, Christophe Faure, Sami Benlamlih, Florian Abel, Michael Beecroft, Mira Francis, Régen Drouin

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Canadian liver journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Antoine CossetteULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
Julie CastillouxPediatric Gastroenterology Division, Department of Pediatrics, CHU de Québec - ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
Chantal BouffardDivision of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, CHUS Research Center, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Julie LaflammePediatric Palliative Care Division, Department of Pediatrics, CHU de Québec - ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
Christophe FaurePediatric Gastroenterology, Sainte-Justine Hospital, Montréal, Quebec, Canada.
Sami BenlamlihULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
Florian AbelAlexion Pharmaceuticals, Inc, Boston, Massachusetts, USA.
Michael BeecroftAlexion Pharmaceuticals, Inc, Boston, Massachusetts, USA.
Mira FrancisAlexion Pharmaceuticals, Inc, Boston, Massachusetts, USA.
Régen DrouinDivision of Medical Genetics, Department of Pediatrics, CHU de Québec - ULaval, and Research Center of the CHU de Québec - ULaval, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
Université Laval · CAPhio Pharmaceuticals (United States) · USCentre Hospitalier Universitaire Sainte-Justine · CAUniversité de Sherbrooke · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This report describes a unique case of long-term survival of a young girl who was diagnosed with severe, rapidly progressive lysosomal acid lipase deficiency (LAL-D; historically "Wolman disease") at three months of age and began receiving therapeutic interventions at four months of age. This disease involves rapidly progressive multisystemic impairments and limited survival (6-12 months) without treatment. Methods: Case report taking into account clinical aspects and patient management including a semi-structured interview with the main family caregiver. Results: Presentation at two months of age: severe malnutrition and chronic diarrhea; hypoalbuminemia; low iron, vitamin A, and vitamin D levels; high triglyceride levels; profound anemia; thrombocytopenia; adrenal calcifications; and mild hepatosplenomegaly. Enzyme replacement therapy (ERT) with sebelipase alfa, parenteral nutrition, and a low-fat diet began at age four months. The patient has received sebelipase alfa for >5 years with good tolerability and is thriving, with a body mass index of 16.35 kg/m Conclusions: Formerly fatal in untreated infants, severe LAL-D, when diagnosed early, can be promptly and effectively treated by combining sebelipase alfa ERT, modified diet, involvement of family caregivers, and multidisciplinary team collaboration.

Indexed as

autosomal recessiveenzyme replacement therapyfamily caregiverlysosomal storage diseasesultrarare disease

Identifiers

PMID36133901
PMCPMC9473556
OpenAlexW4282054086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.